Land Sally, Cunningham Philip, Zhou Jialun, Frost Kevin, Katzenstein David, Kantor Rami, Chen Yi-Ming Arthur, Oka Shinichi, DeLong Allison, Sayer David, Smith Jeffery, Dax Elizabeth M, Law Matthew
National Serology Reference Laboratory, Australia.
J Virol Methods. 2009 Aug;159(2):185-93. doi: 10.1016/j.jviromet.2009.03.016. Epub 2009 Mar 26.
The TREAT Asia (Therapeutics, Research, Education, and AIDS Training in Asia) Network is building capacity for Human Immunodeficiency Virus Type-1 (HIV-1) drug resistance testing in the region. The objective of the TREAT Asia Quality Assessment Scheme - designated TAQAS - is to standardize HIV-1 genotypic resistance testing (HIV genotyping) among laboratories to permit rigorous comparison of results from different clinics and testing centres. TAQAS has evaluated three panels of HIV-1-positive plasma from clinical material or low-passage, culture supernatant for up to 10 Asian laboratories. Laboratory participants used their standard protocols to perform HIV genotyping. Assessment was in comparison to a target genotype derived from all participants and the reference laboratory's result. Agreement between most participants at the edited nucleotide sequence level was high (>98%). Most participants performed to the reference laboratory standard in detection of drug resistance mutations (DRMs). However, there was variation in the detection of nucleotide mixtures (0-83%) and a significant correlation with the detection of DRMs (p<0.01). Interpretation of antiretroviral resistance showed approximately 70% agreement among participants when different interpretation systems were used but >90% agreement with a common interpretation system, within the Stanford University Drug Resistance Database. Using the principles of external quality assessment and a reference laboratory, TAQAS has demonstrated high quality HIV genotyping results from Asian laboratories.
“亚太地区艾滋病治疗、研究、教育及培训”（TREAT Asia）网络正在提升该地区对1型人类免疫缺陷病毒（HIV-1）耐药性检测的能力。“亚太地区质量评估计划”（TREAT Asia Quality Assessment Scheme，简称TAQAS）的目标是使各实验室的HIV-1基因型耐药性检测（HIV基因分型）标准化，以便能严格比较不同诊所和检测中心的结果。TAQAS已对来自临床样本或低传代培养上清液的三组HIV-1阳性血浆进行了评估，参与评估的有多达10家亚洲实验室。实验室参与者使用各自的标准方案进行HIV基因分型。评估是将结果与所有参与者得出的目标基因型以及参考实验室的结果进行比较。在编辑后的核苷酸序列水平上，大多数参与者之间的一致性很高（>98%）。大多数参与者在检测耐药性突变（DRMs）方面达到了参考实验室的标准。然而，在核苷酸混合物的检测方面存在差异（0-83%），且与DRMs的检测存在显著相关性（p<0.01）。在斯坦福大学耐药数据库中，当使用不同的解读系统时，参与者对抗逆转录病毒耐药性的解读显示约70%的一致性，但使用共同解读系统时一致性>90%。通过外部质量评估原则和参考实验室，TAQAS已证明亚洲实验室能得出高质量的HIV基因分型结果。
